Clark M L, Paredes A, Costiloe J P, Fulkerson F G, Wood F
Dis Nerv Syst. 1977 Jan;38(1):7-10.
In a double-blind, placebo controlled design in chronic schizophrenic inpatients using 50 mg. and 100 mg. LOX, an attempt was made to replicate the findings of a previous study and to establish the dose-level and duration of treatment optimal for this kind of patient. Multiple regression analysis adjusting for dose, age, duration of illness, and baseline values indicated that 100 mg. LOX was an effective dose as previously shown. In contrast to the previous study, significant response effects were found by the 4th week. In addition, the dose was linearly related to response on nearly all the variables. The principal side effects were drowsiness and extrapyramidal signs.
在一项针对慢性精神分裂症住院患者的双盲、安慰剂对照设计中，使用50毫克和100毫克的LOX，旨在重复先前研究的结果，并确定针对这类患者的最佳治疗剂量水平和疗程。对剂量、年龄、病程和基线值进行调整的多元回归分析表明，100毫克的LOX如先前所示是有效剂量。与先前的研究不同，在第4周时发现了显著的反应效果。此外，剂量与几乎所有变量的反应呈线性相关。主要副作用是嗜睡和锥体外系症状。
